Cost comparison by treatment arm and center-level variations in cost and inpatient days on the phase III high-risk B acute lymphoblastic leukemia trial AALL0232.

Cancer Med · 2018 · PMC5773964 · PMID 29274118

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

approached significanceno p-value reported

The cost comparison between DEX and PRED revealed that total inpatient costs for DEX were significantly greater in the adjusted analysis than for PRED during the induction period, and this difference approached significance for the entire protocol therapy timeframe.

also in 8,237 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.